Enliven Therapeutics (ELVN) Expected to Announce Quarterly Earnings on Tuesday

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.51) per share for the quarter.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. On average, analysts expect Enliven Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Enliven Therapeutics Stock Performance

NASDAQ ELVN traded down $0.12 during trading hours on Friday, hitting $18.51. The company had a trading volume of 511,962 shares, compared to its average volume of 260,554. Enliven Therapeutics has a 1-year low of $13.30 and a 1-year high of $30.03. The business has a 50 day moving average of $19.06 and a 200-day moving average of $22.04. The company has a market cap of $908.21 million, a PE ratio of -9.74 and a beta of 1.07.

Insider Activity

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 5,000 shares of Enliven Therapeutics stock in a transaction on Monday, April 21st. The shares were sold at an average price of $16.07, for a total value of $80,350.00. Following the sale, the insider now directly owns 997,688 shares in the company, valued at approximately $16,032,846.16. The trade was a 0.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock in a transaction on Monday, March 17th. The stock was sold at an average price of $20.83, for a total transaction of $260,375.00. Following the transaction, the chief executive officer now directly owns 990,392 shares of the company's stock, valued at approximately $20,629,865.36. This trade represents a 1.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 76,111 shares of company stock worth $1,493,145. 29.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, HC Wainwright increased their price objective on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the stock a "buy" rating in a report on Friday, March 21st.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.